Skip to main content
OpenTrials
Completed

NCT Number: NCT00287196

Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes

This trial seeks to establish the role of post-operative radiotherapy in patients who have had surgery for melanoma involving lymph nodes and who are at high risk of recurrence.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

Loading trial locations.

About this study

This is a randomised phase III trial which is being performed on patients at high risk of local recurrence after having a lymphadenectomy for stage 3 melanoma. The control arm is surgery alone with radiotherapy reserved for those who recur. The study arm is surgery plus post-operative radiotherapy. All 3 major node sites are eligible. The radiation dose administered is 48Gy in 20 fractions. It is likely to be the only study of its kind ever performed. The target is 230 patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Regional macroscopic nodal metastatic melanoma in one nodal basin region only which has been completely resected.
  • melanoma involving lymph nodes at high risk of local recurrence (details in protocol)
  • No evidence of metastases
  • No active major cancer within 5 years
  • Normal blood tests
  • WHO performance status of 0 or 1
  • Radiotherapy must be able to be commenced within 12 weeks of lymphadenectomy
  • Patient must not be pregnant and if fertile must use a medically acceptable contraceptive throughout treatment
  • No major concurrent illnesses likely to cause death within 2 years
  • Written informed consent has been given

Exclusion criteria

  • Evidence of active or previous local recurrence or in transit disease
  • Evidence of distant metastases on clinical or radiological investigation
  • Patients with prior cancers

Treatment and study plan

Radiotherapy

Radiation

48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.

Other names: Radiation

Primary outcomes

  1. Locoregional control

    Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)

Secondary outcomes

  1. Disease-free survival

    Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)

  2. Overall survival

    Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)

  3. Toxicity

    Time frame: Interim analysis will occur on annual basis.

  4. Quality of life

    Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)

Sponsors and collaborators

Lead sponsor

Trans Tasman Radiation Oncology Group

Other

Collaborators

  • Australian and New Zealand Intensive Care Society Clinical Trials Group
  • University Medical Center Groningen

Registry information

Official study title

Randomised Clinical Trial of Surgery Versus Surgery Plus Adjuvant Radiotherapy for Regional Control in Patients With Completely Resected Macroscopic Nodal Metastatic Melanoma

Important dates

Study start
2002
Primary completion
2008
Study completion
2011
First posted
Feb 6, 2006
Registry last updated
Jun 25, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.